תוצאות הרבעון הרביעי של החברה עמדו בציפיות, והראו עלייה במספר החשבונות. בערך 3,000 מתוך 7,000 החשבונות הכוללים של Revance הזמינו את Daxxify, והמספר הכולל של החשבונות גדל מ-5,000 בסוף 2022,
תוצאות הרבעון הרביעי של החברה עמדו בציפיות, והראו עלייה במספר החשבונות. בערך 3,000 מתוך 7,000 החשבונות הכוללים של Revance הזמינו את Daxxify, והמספר הכולל של החשבונות גדל מ-5,000 בסוף 2022,
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revance Therapeutics (RVNC – Research Report), VYNE Therapeutics (VYNE – Research Report) and Ironwood Pharma (IRWD – Research Report).
Revance Therapeutics (RVNC)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on Revance Therapeutics, with a price target of $9.00. The company’s shares closed last Thursday at $6.96, close to its 52-week low of $5.00.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $16.63 average price target.
See Insiders’ Hot Stocks on TipRanks >>
VYNE Therapeutics (VYNE)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics today and set a price target of $5.75. The company’s shares closed last Thursday at $2.21, close to its 52-week low of $1.67.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VYNE Therapeutics with a $5.75 average price target.
Ironwood Pharma (IRWD)
JMP Securities analyst Jason Butler reiterated a Buy rating on Ironwood Pharma today and set a price target of $23.00. The company’s shares closed last Thursday at $9.10, close to its 52-week low of $8.08.
According to TipRanks.com, Butler is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ironwood Pharma with a $18.50 average price target, implying a 73.5% upside from current levels. In a report issued on February 15, Wells Fargo also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RVNC:
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $20.00. The company’s shares
Piper Sandler lowered the firm’s price target on Revance to $20 from $42 and keeps an Overweight rating on the shares. The firm notes Revance reported a Q4 adjusted net